TGTX 13.54 Tg Therapeutics $TGTX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 3:21 PM

TGTX 13.54 Tg Therapeutics $TGTX Hit a 52 week high of 13.98 Closing the day 09:44 at 13.54 -0.33 -2.38% With a day low of 13.51 and a total volume of 47,764.

TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/

TGTX Tg Therapeutics Recent Headline News

5 Momentum Stocks Currently on the Move with More Potential Upside
at The Street - Thu Nov 13, 11:34AM CST
Achillion, Groupon, Orexigen, Rackspace and TG Therapeutics have had strong recent moves and are showing no sign of slowing.
OREX: 5.49 (-0.37), RAX: 43.77 (+0.44), ACHN: 14.04 (+0.55), TGTX: 13.93 (+0.06), GRPN: 7.86 (+0.09)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 85.75 (+0.80), OREX: 5.49 (-0.37), PCMI: 8.87 (-0.07), CYAN: 7.09 (+0.57), ACHN: 14.04 (+0.55), TGTX: 13.93 (+0.06), AGIO: 84.08 (-2.41), LIOX: 5.19 (-0.06), SAJA: 6.21 (+0.31), PLNR: 6.71 (+0.04)

TG Therapeutics' (TGTX) CEO Michael Weiss on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:03PM CST

TGTX: 13.93 (+0.06)

TG Therapeutics net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:10AM CST

TGTX: 13.93 (+0.06)

TG Therapeutics posts 3Q loss
Automated Insights - Tue Nov 11, 4:11AM CST
NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Tuesday reported a loss of $17.5 million, or 51 cents per share, in its third quarter.
TGTX: 13.93 (+0.06)

TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST

TGTX: 13.93 (+0.06)

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 13.93 (+0.06)

TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST

TGTX: 13.93 (+0.06)

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 13.93 (+0.06)

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 13.93 (+0.06)

Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 13.93 (+0.06)

Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 58.91 (-0.63), TGTX: 13.93 (+0.06), LGND: 57.58 (-0.38), AMGN: 156.76 (-4.09)

TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 13.93 (+0.06)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 13.93 (+0.06)

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"

. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 13.93 (+0.06)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 85.75 (+0.80), ABAX: 54.75 (-0.26), TGTX: 13.93 (+0.06), EGRX: 12.62 (-0.03)

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 13.93 (+0.06)

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 13.93 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

B2B Growth Hinges on Narrative Coherence, Study Shows

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Robotics in Cleaning: 2026 Sees Double Adoption Rates

Cleaning Industry Eyes Robotic Solutions Amid Labor Squeeze In a twist that's got industry veterans nodding knowingly, the cleaning industry is tipping towards automation. The recent 2026 Building Service Contractor Market Study reveals a massive leap: 32% of building service contractors (BSCs) plan to embrace robotic floor equipment in the coming year. That's a...

Paula's Choice Elevates Skincare Game with New Campaign

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...

Jacob Walthour to Be Honored for Economic Leadership

The Honoring of Leadership That Goes Beyond Business In a world where financial influence often feels like it funnels into the same familiar pockets, the news of Jacob Walthour Jr.'s upcoming recognition feels like a fresh breeze of change. The Alpha Phi Alpha's Alpha Alpha Lambda Chapter is rolling out the red carpet at its Centennial Gala for Walthour, throwing him into...

Goddess Maintenance Co. Eyes BeautyMatter Award

Challenging the Haircare Norm with Confidence Goddess Maintenance Co. doesn't just draft a fresh play in the beauty industry playbook—it's ripping out the old pages and setting a new standard. This ain't your granny's haircare game anymore, folks. They're up for a 2026 BeautyMatter Award, a nod to their gut-busting innovation in the conditioner category with their star...

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Propensity Rockets to No. 70 on the 2026 Inc. 5000 List

Hold onto your hats, folks—Propensity just blasted its way to Number 70 on the Inc. 5000 for 2026. That's quite a leap from the 2,591 spot just last year. If you're scratching your head wondering what's behind this meteoric rise, it’s all about AI and knowing which buyer signals really matter. The AI Advantage in B2B The B2B marketing space isn't exactly the new Wild...

BMAP Expands: Bridging Borders in Legal Advocacy

Breaking Down BMAP's Unique Approach Just when you thought you've seen it all, along comes LMU Loyola Law School swinging the doors wide open with their Binational Migrant Advocacy Project, or as we’re affectionately calling it, BMAP. It's a mouthful, sure, but ain't it something? This project isn't just another feather in academia's cap—it's a relentless counterpunch...

Ransoms and Mega-Losses Surge in Cyber Claims Study

Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...

Solar Fencing Revolutionizes North Texas Homes

Fences Go Solar: Welcome to the Future Land of fences and sunshine, North Texas is about to see a game changer in home improvement. Southwest Fence & Deck is rolling out the red carpet as an Authorized SOL Fence Installation Partner, putting solar power right in your backyard. Yeah, there have been sparks of innovation in plenty of fields, but who expected fences to join...